22APR2017

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS
BOARD CERTIFIED IN PSYCHIATRY
521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472
T: (617)744-8542 • F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

EDUCATION/SCHOLARSHIP

HARVARD MEDICAL SCHOOL, Cambridge, MA
Resident in Psychiatry, June 1975

Chief Resident: Clinical Fellow of Harvard Medical School; Assistant Clinical Director of In-Patient Psychiatry, Mount Auburn Hospital, Cambridge, MA.

SUNY UPSTATE MEDICAL UNIVERSITY, Syracuse, NY
Resident in Psychiatry, May 1974
Doctor of Medicine, May 1971
CITY COLLEGE OF NEW YORK, New York, NY
Bachelor of Science, May 1967
BRONX HIGH SCHOOL OF SCIENCE, Bronx, NY

PSYCHIATRIC CLINICAL RESEARCH EXPERIENCE

ADAMS CLINICAL TRIALS, Watertown, MA December 2010 - Present

Medical Director: Lead research team at dedicated psychiatric clinical research site with a focus on testing treatments for mood disorders, eating disorders, and substance use disorders for all age groups in Phase II and III trials. Staff consists of eight full-time study coordinators, five physicians, and two psychologists.

Principal Investigator on the 38 clinical trials listed below:

NCT03107026 2017

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

NCT02951988 2017

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

NCT03002077 2017

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT02431806 2017

Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

NCT02932943 2016

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder

NCT02497287 2016

HARVARD MEDICAL SCHOOL, Cambridge, MA
Resident in Psychiatry, June 1975

Chief Resident: Clinical Fellow of Harvard Medical School; Assistant Clinical Director of In-Patient Psychiatry, Mount Auburn Hospital, Cambridge, MA.

SUNY UPSTATE MEDICAL UNIVERSITY, Syracuse, NY
Resident in Psychiatry, May 1974
Doctor of Medicine, May 1971
CITY COLLEGE OF NEW YORK, New York, NY
Bachelor of Science, May 1967
BRONX HIGH SCHOOL OF SCIENCE, Bronx, NY

PSYCHIATRIC CLINICAL RESEARCH EXPERIENCE

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS
BOARD CERTIFIED IN PSYCHIATRY
521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472
T: (617)744-8542 • F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

NCT02436239 2016

Safety of Vilazodone in Pediatric Patients with Major Depressive Disorder

NCT01878292 2016

Safety and Efficacy of Vilazodone in Pediatric Patients with Major Depressive Disorder

NCT02684279 2016

An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults with Binge-eating Disorder

NCT02564588 2016

A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults with Moderate to Severe Binge Eating Disorder

NCT02510014 2015

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

NCT02357901 2015

A Phase 3, A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP-6000) Over 24 Weeks in Treatment-Seeking Subjects with Opioid Use Disorder

NCT01998633 2015

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (with or without Decreased Arousal)

NCT01878292 2015

A Phase 3 Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder

NCT02288325 2014

A Phase 4 Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder

NCT02141399 2014

A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive

NCT01878292 2016

Safety and Efficacy of Vilazodone in Pediatric Patients with Major Depressive Disorder

NCT02684279 2016

An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults with Binge-eating Disorder

NCT02564588 2016

A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults with Moderate to Severe Binge Eating Disorder

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS
BOARD CERTIFIED IN PSYCHIATRY
521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472
T: (617)744-8542 • F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

NCT02009163 2014

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder.

NCT01312909 2013

A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study With Follow-Up Evaluating The Safety and Efficacy Of Varenicline For Smoking Cessation in Healthy Adolescent Smokers

NCT01944969 2013

Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients with Major Depressive Disorder

NCT01837797 2013

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3mg/Day) as Adjunctive Treatment in Elderly Patients with Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01813019 2013

A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01878292 2013

A Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients with Major Depressive Disorder.

NCT01457677 2013

A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment.

NCT01360866 2013

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial.

NCT01727726 2013

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder.

NCT01312909 2013

A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study With Follow-Up Evaluating The Safety and Efficacy Of Varenicline For Smoking Cessation in Healthy Adolescent Smokers

NCT01944969 2013

Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients with Major Depressive Disorder

NCT01837797 2013

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS
BOARD CERTIFIED IN PSYCHIATRY
521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472
T: (617)744-8542 • F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

NCT01657019 2012

A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.

NCT01718509 2012

The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder.

NCT01436175 2011

A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant.

NCT01436149 2011

The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant.

NCT01110902 2011

A 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD).

NCT01395147 2011

A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder.

NCT01179516 2011

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder.

NCT01121536 2011

A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated with Bipolar I

Disorder, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder.

NCT01718509 2012

The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder.

NCT01436175 2011

A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant.

NCT01436149 2011

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS
BOARD CERTIFIED IN PSYCHIATRY
521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472
T: (617)744-8542 • F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

NCT01056289 2010

A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation.

NCT00887224 2010

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder

ATLANTIC CLINICAL RESEARCH, LLC, Watertown, MA 2004 - 2010

Principal Investigator on the 4 clinical trials listed below:

NCT00824291 2009

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release.

NCT00483548 2007

A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression.

NCT00235508 2005

The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.

NCT00368030 2004

Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Related to MDD Acronym: DREAMDD.

OTHER CLINICAL RESEARCH EXPERIENCE

ATLANTIC CLINICAL RESEARCH, LLC, Watertown, MA

Sub-Investigator on the 8 clinical trials listed below:

NCT01156415 2011

A 52-week, Multi-center, Open-label Study of the Safety and Tolerability of Agomelatine Sublingual Tablets in Patients With Major Depressive Disorder (MDD).

NCT01056289, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation.

NCT00887224 2010

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder

ATLANTIC CLINICAL RESEARCH, LLC, Watertown, MA 2004 - 2010

Principal Investigator on the 4 clinical trials listed below:

NCT00824291 2009

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release.

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS

BOARD CERTIFIED IN PSYCHIATRY

521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472

T: (617)744-8542• F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

NCT01350141 2010

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety, And Tolerability Of PF-04950615 (RN316)Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin

NCT01289990 2010

A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23

NCT01131676 2010

BI 10773 add-on to Usual Care Compared With Usual Care Alone in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

NCT01194830 2009

A Phase IIIB, 24-week, randomized, placebo-controlled, double-blinded, efficacy and safety study of linagliptin (BI 1356) in Black/African American patients with type 2 diabetes with a MTT sub-study.

NCT01042769 2009

A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Melitus (T2D).

NCT00788944 2008

An Open-Label Study To Evaluate The Prevalence Of Phenotypic Poor Metabolizers At CYP2D6 Among Venlafaxine-Treated Outpatients With Depression.

PROFESSIONAL CLINICAL EXPERIENCE

PRIVATE PSYCHIATRIC PRACTICE, Everett, MA, and Watertown, MA July 1975 - Present

Opioid Dependency Treatment: Prescribe Suboxone for the treatment of 80 patients suffering from opioid dependency with a special waiver from the Drug Enforcement Administration under the Drug Addiction Treatment Act of 2000. Treatment consists of a comprehensive out-patient program with both individual and group therapy. Medication management is closely monitored and combined with frequent urine toxicology screens. (January 2006 - present).

Everett Chronic Pain Program: Direct out-patient program for chronic intractable pain syndrome patients. [illegible]

Tolerability Of PF-04950615 (RN316)Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin

NCT01289990 2010

A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23

NCT01131676 2010

BI 10773 add-on to Usual Care Compared With Usual Care Alone in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

DANIEL RUTRICK, M.D.

MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATOR AT ADAMS CLINICAL TRIALS
BOARD CERTIFIED IN PSYCHIATRY
521 MOUNT AUBURN STREET, SUITES 107, 109, 209 • WATERTOWN, MASSACHUSETTS 02472
T: (617)744-8542 • F: (617)744-8544 • DRUTRICK@ADAMSCLINICAL.COM

practitioners. Manage group therapies for disability; grief; mid-life crisis; panic disorder; chronic pain; and social anxiety disorder. (July 1975 - present).

BOSTON PAIN CENTER, SPAULDING REHABILITATION HOSPITAL, Boston, MA 1976 - 1988

Consultant: Advised multi-disciplinary in-patient treatment program focusing on chronic intractable low back pain and headaches. Program consisted of behavioral and dynamic psychotherapy in association with physical therapy, and required psychopharmacology, milieu management, and crisis intervention when patients suffered from depressive and other psychiatrically diagnosable reactions to chronic pain.

MOUNT AUBURN HOSPITAL, Watertown, MA September 1974 - June 1975

Assistant Director of In-Patient Psychiatry: Hired staff, developed orientation program, determined admissions. and managed a sixteen bed voluntary, adult, in-patient unit. Diagnosed and managed treatment for patients suffering from bipolar disorder, major depression with suicidal behavior, personality disorders, and psychotic states. Treatment consisted individual, group, and psychopharmacological therapy.

HOSPITAL AFFILIATIONS

LAWRENCE MEMORIAL HOSPITAL OF MEDFORD, Medford, MA	2001 - 2014
MELROSE-WAKEFIELD HOSPITAL, Melrose, MA	2001 - 2014
ST. ELIZABETH'S MEDICAL CENTER, Brighton, MA	1976 - Present
MOUNT AUBURN HOSPITAL, Cambridge, MA	1975 - Present

PUBLICATIONS

Combined Psychotherapy of Chronic Pain Patients on a Pain Unit. Hospital Practice. September, 1983.

Psychiatrist's View of Chronic Pain. International Anesthesiology Clinics. Volume 21, No. 4, Winter, 1983.

Psychodynamic Psychotherapy of Chronic Pain Patient. With Gerald Aronoff, M.D., 1985.

Mavoglurant in Obsessive-Compulsive Disorder Resistant to Selective Serotonin Reuptake Inhibitor: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study. Advances in Therapy. With Dan. J Stein, FRCPC, PhD, Ganesan Subramanian, PhD, Brian Smith, PhD, Maurizio Fava, MD, Gregor Hasler, MD, Jang-Ho Cha, MD, PhD, Toni Donchev, MD, PhD, Magdalena Ocwieja, PhD, and Baltazar GomezMancilla, M.D., Ph.D., June, 2016.

PROFESSIONAL MEMBERSHIPS

American Psychiatric Association; Massachusetts Psychiatric Association; American Society of Clinical Psychopharmacology; Association of Clinical Research Professionals.

BOSTON PAIN CENTER, SPAULDING REHABILITATION HOSPITAL, Boston, MA 1976 - 1988

Consultant: Advised multi-disciplinary in-patient treatment program focusing on chronic intractable low back pain and headaches. Program consisted of behavioral and dynamic psychotherapy in association with physical therapy, and required psychopharmacology, milieu management, and crisis intervention when patients suffered from depressive and other psychiatrically diagnosable reactions to chronic pain.

MOUNT AUBURN HOSPITAL, Watertown, MA September 1974 - June 1975

Assistant Director of In-Patient Psychiatry: Hired staff, developed orientation program, determined admissions. and managed a sixteen bed voluntary, adult, in-patient unit. Diagnosed and managed treatment for patients suffering from bipolar disorder, major depression with suicidal behavior, personality disorders, and psychotic states. Treatment consisted individual, group, and psychopharmacological therapy.

HOSPITAL AFFILIATIONS